These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
673 related articles for article (PubMed ID: 33959860)
21. Changing prescription pattern of omeprazole among patients receiving clopidogrel. Kashour T; Al-Tannir M; Bahamid R Int Heart J; 2014; 55(2):93-5. PubMed ID: 24632962 [TBL] [Abstract][Full Text] [Related]
22. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers. Funck-Brentano C; Szymezak J; Steichen O; Ducint D; Molimard M; Remones V; Azizi M; Gaussem P Arch Cardiovasc Dis; 2013 Dec; 106(12):661-71. PubMed ID: 24246616 [TBL] [Abstract][Full Text] [Related]
23. CYP2C19 loss-of-function alleles and use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel. Ramste M; Ritvos M; Häyrynen S; Kiiski JI; Niemi M; Sinisalo J Clin Transl Sci; 2023 Oct; 16(10):2010-2020. PubMed ID: 37551775 [TBL] [Abstract][Full Text] [Related]
24. The influence of omeprazole on platelet inhibition of clopidogrel in various CYP2C19 mutant alleles. Liu Q; Dang DS; Chen YF; Yan M; Shi GB; Zhao QC Genet Test Mol Biomarkers; 2012 Nov; 16(11):1293-7. PubMed ID: 23046071 [TBL] [Abstract][Full Text] [Related]
25. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Furuta T; Iwaki T; Umemura K Br J Clin Pharmacol; 2010 Sep; 70(3):383-92. PubMed ID: 20716239 [TBL] [Abstract][Full Text] [Related]
26. Drug Interaction Between Clopidogrel and Ranitidine or Omeprazole in Stable Coronary Artery Disease: A Double-Blind, Double Dummy, Randomized Study. Furtado RHM; Giugliano RP; Strunz CMC; Filho CC; Ramires JAF; Filho RK; Neto PAL; Pereira AC; Rocha TR; Freire BT; D'Amico EA; Nicolau JC Am J Cardiovasc Drugs; 2016 Aug; 16(4):275-284. PubMed ID: 27289472 [TBL] [Abstract][Full Text] [Related]
27. Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors. Tomek A; Matʼoška V; Frýdmanová A; Magerová H; Šrámek M; Paulasova-Schwabová J; Růžičková T; Janský P; Šarbochová I; Hadačová I; Kaplan V; Lacinová Z; Táborský L; Serebruany V Am J Ther; 2018; 25(2):e202-e212. PubMed ID: 29509167 [TBL] [Abstract][Full Text] [Related]
28. Risk of major adverse cardiovascular events for concomitant use of clopidogrel and proton pump inhibitors in patients inheriting CYP2C19 loss-of-function alleles: meta-analysis. Biswas M; Rahaman S; Biswas TK; Ibrahim B Int J Clin Pharm; 2021 Oct; 43(5):1360-1369. PubMed ID: 33774763 [TBL] [Abstract][Full Text] [Related]
29. Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel. Sun W; Li Y; Li J; Zhang Z; Zhu W; Liu W; Cai Q; Wang X; Cao L; Bai W; Fan X; Ma M; Guo R; Liu X; Xu G Platelets; 2015; 26(6):558-62. PubMed ID: 25207801 [TBL] [Abstract][Full Text] [Related]
30. Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy. Fernando H; Dart AM; Peter K; Shaw JA Thromb Haemost; 2011 Jun; 105(6):933-44. PubMed ID: 21544314 [TBL] [Abstract][Full Text] [Related]
31. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Jeong YH; Tantry US; Kim IS; Koh JS; Kwon TJ; Park Y; Hwang SJ; Bliden KP; Kwak CH; Hwang JY; Gurbel PA Circ Cardiovasc Interv; 2011 Dec; 4(6):585-94. PubMed ID: 22045970 [TBL] [Abstract][Full Text] [Related]
37. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143 [TBL] [Abstract][Full Text] [Related]
38. Concomitant Use of Proton-Pump Inhibitors and Clopidogrel Increases the Risk of Adverse Outcomes in Patients With Ischemic Stroke Carrying Reduced-Function CYP2C19*2. Yi X; Han Z; Zhou Q; Cheng W; Lin J; Wang C Clin Appl Thromb Hemost; 2018 Jan; 24(1):55-62. PubMed ID: 27637911 [TBL] [Abstract][Full Text] [Related]
39. Platelet inhibitory effect of clopidogrel in patients treated with omeprazole, pantoprazole, and famotidine: a prospective, randomized, crossover study. Arbel Y; Birati EY; Finkelstein A; Halkin A; Kletzel H; Abramowitz Y; Berliner S; Deutsch V; Herz I; Keren G; Banai S Clin Cardiol; 2013 Jun; 36(6):342-6. PubMed ID: 23630016 [TBL] [Abstract][Full Text] [Related]
40. Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution? Kenngott S; Olze R; Kollmer M; Bottheim H; Laner A; Holinski-Feder E; Gross M Eur J Med Res; 2010 May; 15(5):220-4. PubMed ID: 20562062 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]